Top in cardiology: Effects of high sedentary time, adding dapagliflozin to HFrEF therapy
Click Here to Manage Email Alerts
Recent data showed that 8 or more hours of daily sedentary leisure time increased the risk for stroke in people aged younger than 60 years. It was the top story in cardiology last week.
Another top story investigated the cost-effectiveness of adding the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) to therapy for patients with heart failure with reduced ejection fraction (HFrEF). Researchers projected that the addition of dapagliflozin was associated with an incremental cost-effectiveness ratio of $68,300 per quality-adjusted life-year gained.
Read these and more top stories in cardiology below:
Sedentary leisure time of at least 8 hours per day tied to stroke risk in younger adults
Among adults younger than 60 years with low physical activity, those who had at least 8 hours per day of sedentary leisure time had elevated risk for stroke, according to findings published in Stroke. Read more.
Adding dapagliflozin to medical therapy efficacious, cost-effective in HFrEF
In a simulation model, the addition of dapagliflozin to guideline-directed medical therapy in patients with HFrEF improved long-term clinical outcomes while proving cost-effective at current U.S. prices. Read more.
FDA approves empagliflozin for treatment of HFrEF in patients with or without diabetes
Boehringer Ingelheim and Eli Lilly announced the FDA has approved empagliflozin (Jardiance) to reduce risk for cardiovascular death and HF hospitalization in adults with HFrEF regardless of whether they have diabetes. Read more.
Screening for asymptomatic AF brings potential benefits, many questions
Atrial fibrillation accounts for 454,000 hospitalizations and 158,000 deaths annually, according to the CDC. Many with AF have symptoms, but many do not, leading to the question of whether screening in asymptomatic individuals is needed. Read more.
COVID-19 a risk factor for acute MI, ischemic stroke
A new study identified COVID-19 as an independent risk factor for acute myocardial infarction and ischemic stroke. Read more.